See more : Coliseum Acquisition Corp. (MITAW) Income Statement Analysis – Financial Results
Complete financial analysis of Apollomics, Inc. (APLM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Apollomics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Niigata Kotsu Co., Ltd. (9017.T) Income Statement Analysis – Financial Results
- NB Private Equity Partners Limited (NBPVF) Income Statement Analysis – Financial Results
- ISF Limited (ISFL.BO) Income Statement Analysis – Financial Results
- Archer Materials Limited (ARRXF) Income Statement Analysis – Financial Results
- New Wave Holdings Corp. (SPOR.CN) Income Statement Analysis – Financial Results
Apollomics, Inc. (APLM)
About Apollomics, Inc.
Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 821.00K | 323.00K | 2.00K | 1.84M | 0.00 |
| Cost of Revenue | 694.00K | 775.00K | 681.00K | 609.00K | 369.00K |
| Gross Profit | 127.00K | -452.00K | -679.00K | 1.23M | -369.00K |
| Gross Profit Ratio | 15.47% | -139.94% | -33,950.00% | 66.87% | 0.00% |
| Research & Development | 34.19M | 35.46M | 35.57M | 31.44M | 18.44M |
| General & Administrative | 20.64M | 9.95M | 15.29M | 11.04M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 20.64M | 9.95M | 15.29M | 11.04M | 5.94M |
| Other Expenses | 0.00 | -196.25M | -41.95M | -29.88M | 0.00 |
| Operating Expenses | 54.14M | 44.39M | 50.27M | 40.75M | 24.38M |
| Cost & Expenses | 54.83M | 44.39M | 50.27M | 40.75M | 24.75M |
| Interest Income | 0.00 | 431.00K | 467.00K | 330.00K | 702.00K |
| Interest Expense | 150.00K | 93.00K | 83.00K | 72.00K | 46.00K |
| Depreciation & Amortization | 694.00K | 775.00K | 681.00K | 609.00K | 369.00K |
| EBITDA | -171.75M | -239.94M | -94.03M | -74.22M | -45.34M |
| EBITDA Ratio | -20,919.24% | -74,128.79% | -4,553,500.00% | -3,997.61% | 0.00% |
| Operating Income | -54.83M | -240.21M | -91.75M | -74.09M | -24.75M |
| Operating Income Ratio | -6,678.93% | -74,368.73% | -4,587,550.00% | -4,030.74% | 0.00% |
| Total Other Income/Expenses | -117.76M | -196.75M | -44.53M | -34.26M | -21.00M |
| Income Before Tax | -172.59M | -240.81M | -94.80M | -74.91M | -45.75M |
| Income Before Tax Ratio | -21,022.05% | -74,554.18% | -4,739,800.00% | -4,075.35% | 0.00% |
| Income Tax Expense | 10.00K | 1.00K | 1.00K | -85.00K | 153.00K |
| Net Income | -172.60M | -240.81M | -94.80M | -74.82M | -45.91M |
| Net Income Ratio | -21,023.26% | -74,554.49% | -4,739,850.00% | -4,070.73% | 0.00% |
| EPS | -2.32 | -2.77 | -1.09 | -0.86 | -0.53 |
| EPS Diluted | -2.32 | -2.77 | -1.09 | -0.86 | -0.53 |
| Weighted Avg Shares Out | 74.40M | 86.80M | 86.80M | 86.80M | 86.80M |
| Weighted Avg Shares Out (Dil) | 74.40M | 86.80M | 86.80M | 86.80M | 86.80M |
Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
FOSTER CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced Company management will be presenting...
Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress
FOSTER CITY, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial results for the first...
Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial
43% overall response rate: Six confirmed responses (including one complete response in metastatic non-small cell lung cancer and five partial responses) confirmed by RECIST 1.1 out of 14 patients with solid tumors harboring MET gene fusions 43% overall response rate:...
Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement
FOSTER CITY, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced today that it received written notification...
Apollomics Announces Updated Strategic Focus and Leadership Team Changes
Focus on vebreltinib study enrollment for non-small cell lung cancer (NSCLC) patients with Met Amplification mutations targets greatest unmet medical need Focus on vebreltinib study enrollment for non-small cell lung cancer (NSCLC) patients with Met Amplification mutations targets greatest unmet...
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
Apollomics' partner in China, Avistone, received approval from National Medical Products Administration of China to expand the use of vebreltinib to the treatment of gliomas with PTPRZ1-MET fusion gene
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Preclinical studies demonstrate vebreltinib is effective for a variety of tumor types carrying MET-driver alterations, and effective for overcoming MET-amplification dependent resistance to EGFR therapies in EGFR-positive non-small cell lung cancer Preclinical studies demonstrate vebreltinib is effective for a variety...
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
FOSTER CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late- stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial results for the...
Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
FOSTER CITY, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that Matthew Plunkett, Ph.D., has been appointed as Chief Financial Officer of Apollomics.
Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
FOSTER CITY, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that Guo-Liang Yu, Ph.D., Chairman and Chief Executive Officer of Apollomics, and Sanjeev...
Source: https://incomestatements.info
Category: Stock Reports